Genmab is recruiting patients for a PHASE1/PHASE2 clinical trial testing pembrolizumab (Keytruda) for mesothelioma.
The trial, designated NCT05579366, aims to enroll up to 764 participants at 56 sites, including locations in Arizona, California, Florida.
About the Study
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors.
Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).
Treatment Approach
This trial uses a PD-1 checkpoint inhibitor that helps the immune system recognize and attack cancer cells.
Key trial details:
- Phase: PHASE1/PHASE2
- Sponsor: Genmab
- Enrollment target: 764
- Status: RECRUITING
Why This Trial Matters
Study Locations
The trial is recruiting at:
- USOR HonorHealth, Arizona
- USOR Arizona Oncology Associates, Arizona
- University of California Los Angeles Medical Center, California
- University of California, San Diego; Moores Cancer Center, California
- USOR Sansum Clinic, California
How to Enroll
Patients interested in this trial should:
- Discuss eligibility with their oncologist
- Review the full eligibility criteria on ClinicalTrials.gov
- Contact the study coordinator for screening